Günther Loidl
Chief Tech/Sci/R&D Officer chez BACHEM HOLDING AG
Fortune : 1 M $ au 31/03/2024
Profil
Le Dr Gnther Loidl est directeur de la technologie chez Bachem Holding AG. Il est membre du conseil d'administration de Bachem AG. Il a obtenu son doctorat à l'Institut Max Planck de biochimie.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
31/12/2022 | 14 995 ( 0,02% ) | 1 M $ | 31/03/2024 |
Postes actifs de Günther Loidl
Sociétés | Poste | Début |
---|---|---|
BACHEM HOLDING AG | Chief Tech/Sci/R&D Officer | 01/01/2015 |
Bachem AG
Bachem AG Pharmaceuticals: MajorHealth Technology Bachem AG engages in the sale and distribution of active pharmaceutical ingredients and research grade products. The firm’s products include peptides and complex organic molecules, as well as new chemical entities and generic active pharmaceutical ingredients. It also focuses on peptide research and development, including custom peptide synthesis. The company was founded by Peter Grogg in 1971 and is headquartered in Bubendorf, Switzerland. | Director/Board Member | 01/01/2000 |
Formation de Günther Loidl
Max Planck Institute of Biochemistry | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
BACHEM HOLDING AG | Health Technology |
Entreprise privées | 1 |
---|---|
Bachem AG
Bachem AG Pharmaceuticals: MajorHealth Technology Bachem AG engages in the sale and distribution of active pharmaceutical ingredients and research grade products. The firm’s products include peptides and complex organic molecules, as well as new chemical entities and generic active pharmaceutical ingredients. It also focuses on peptide research and development, including custom peptide synthesis. The company was founded by Peter Grogg in 1971 and is headquartered in Bubendorf, Switzerland. | Health Technology |